U.S. markets open in 9 hours 7 minutes

Lipocine Inc. (LPCN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4200-0.0100 (-0.70%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.4300
Open1.3789
Bid1.4100 x 43500
Ask1.4200 x 3200
Day's Range1.3800 - 1.4700
52 Week Range0.3010 - 2.4200
Volume1,007,101
Avg. Volume5,076,598
Market Cap124.02M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-0.4260
Earnings DateMar 11, 2021 - Mar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis
    PR Newswire

    Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the publication of preclinical results supporting the therapeutic potential of LPCN 1144 in the treatment of and non-alcoholic steatohepatitis ("NASH") and hepatic fibrosis. The results were featured in a paper entitled "Treatment Potential of LPCN 1144 on Liver Health and Metabolic Regulation in a Non–Genomic, High Fat Diet Induced NASH Rabbit Model" (Comeglio et al), published in the Journal of Endocrinological Investigation (https://doi.org/10.1007/s40618-021-01522-7).

  • Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference
    PR Newswire

    Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference

    Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the ENDO 2021 Conference, to take place March 20-23, 2021. TLANDO is an oral testosterone replacement therapy ("TRT") product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.

  • Lipocine to Present at Two Upcoming Investor Conferences
    PR Newswire

    Lipocine to Present at Two Upcoming Investor Conferences

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James 42nd Annual Institutional Investors Conference and the H.C. Wainwright Global Life Sciences Conference. Both conferences will be held virtually. Presentation details are below.